Latest Asthma News
These soluble IgE moleclues are produced by immune cells called B cells. While targeting IgE in the blood is an effective treatment for moderate-to-severe allergic asthma, this approach doesn't stop IgE production and patients require repeated treatments, explained the researchers at Genentech Inc. in California.
They say they've developed a way to eliminate IgE-producing B cells, a finding that could lead to new long-lasting treatments for asthma and other allergic diseases.
When tested in mice, this method proved highly effective.
Genentech has a financial stake in the research.
The study appears online May 10 in the Journal of Clinical Investigation.
-- Robert Preidt
Copyright © 2010 HealthDay. All rights reserved.